A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

Gilead Sciences Inc. closed 7.92% below its 52-week high of $119.96, which the company achieved on March 10th.

But new research published in JAMA Pediatrics found distinct patterns of long COVID symptoms in young children. Researchers ...

Shares of Gilead Sciences Inc. GILD slid 1.06% to $108.91 Monday, on what proved to be an all-around favorable trading ...

Patients with untreated chronic hepatitis B and metabolic comorbidities face a higher risk for advanced liver fibrosis and ...

The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” first quarter 2025 ...

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Citi analysts reiterated a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) stock and maintained a $125 price target. The ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...